AMERICAN BIOMED, Minimally Invasive Technology (ABMI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : AMERICAN BIOMED, Minimally Invasive Technology (ABMI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lhn5 who wrote (554)	4/25/1998 1:33:00 PM
From: Jeffrey L. Henken	Read Replies (2) of 2887

Remember Larry that even the Japanese trials will be designed to meet FDA protocols as they will be overseen by American BioMed's own Dr Ahn: biz.yahoo.com Masayoshi Kokunbun of K's Projects stated, ''We expect to finalize plans with the Ministry within the next month to expedite the completion of clinical trials for American BioMed's OmniCath(R) Atherectomy Catheter product.'' Clinical trials must be completed prior to registration in Japan, which the company anticipates will take approximately six to eight months. The Japanese protocols will be similar to U.S. requirements, and will be overseen by the company's Principal Clinical Investigator, Dr. Samuel S. Ahn of the University of California, Los Angeles. GO ABMI! Regards, Jeff

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next